CHARLESTOWN, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and ...

For more than two decades, researchers at the University of Basel, Switzerland, have been investigating a severe form of ...

In July, the FDA refused to approve Capricor’s application for Deramiocel for the treatment of cardiomyopathy associated with ...

STATEN ISLAND, N.Y. — In the “Big Heart” department, Mike DiLeo, executive chef at Max’s Esca, played host to “Savor the ...

Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced the launch of KYMBEE™ (deflazacort) Tablets, indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 5 years of age ...

SGT-212 has been granted FDA Rare Pediatric Disease and Fast Track designations - - SGT-212 is the only dual route gene therapy in development to treat Friedreich’s ataxia - CHARLESTOWN, Mass., Dec.

Roche (RHHBY) is upgraded to Buy as strong 2025 growth, new drug launches, and obesity drug potential create an attractive ...

Focused on rare disease therapies, this biotech company reported a significant insider sale amid strong recent share price ...

With three sons with Duchenne MD, columnist Betty Vertin has little time for housework, making her regret not giving the other kids chores.

Earlier this week, Sarepta Therapeutics received FDA approval to begin dosing non-ambulant Duchenne muscular dystrophy patients in Cohort 8 of the ENDEAVOR study, evaluating an enhanced ...

The milestone was earned when Arrowhead achieved the second development milestone event in a Phase 1/2 clinical study of ...